Skip to content

Retinal Oxygen Reactivity in Patients Infected With Human Immunodeficiency Virus (HIV)

Retinal Oxygen Reactivity in Patients Infected With Human Immunodeficiency Virus (HIV).

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00431548
Enrollment
30
Registered
2007-02-06
Start date
Unknown
Completion date
Unknown
Last updated
2007-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections, Ocular Physiology, Retina

Brief summary

Ocular lesions, including cotton wool spots and retinal hemorrhage, are a common feature of HIV infection and acquired immunodeficiency syndrome (AIDS). The aetiology of these apparently vasoocclusive phenomena in HIV related retinopathy is not well understood. Several hypotheses including infectious damage of the retinal vasculature and altered retinal hemodynamics have been postulated. The latter would be compatible with the theory that the retina of HIV patients is hypoxic. However, direct measurement of oxygen tension in the retina is not possible and indirect methods have to be employed. The study objective was to investigate the reactivity in retinal blood flow to 100% oxygen breathing in patients with HIV.

Interventions

Sponsors

Medical University of Vienna
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
19 Years to 70 Years

Inclusion criteria

Group 1 (Patients with HIV) * Aged between 19 and 70 years, male and female * HIV positive patients without HIV-related retinopathy with a CD4+ cell count  500 cells/mm3 stage A2, A3, B2, B3, C2 and C3. * Best corrected visual acuity \>= 0.8 * Ametropy \< 6 dpt Group 2 (Healthy control subjects) * Aged between 19 and 70 years * Age and sex matched to the subjects in the HIV group (group matched) * Matched with regard to the smoking habits in the HIV group * Best corrected visual acuity \>= 0.8 * Ametropy \< 6 dpt

Exclusion criteria

* Evidence of any other eye disease * Diabetes mellitus * Systemic hypertension (defined as SBP \> 150 mmHg or DBP \> 90 mmHg) * Abuse of illegal drugs

Design outcomes

Primary

MeasureTime frame
Reactivity in retinal blood flow during 100% O2 breathing expressed as percent change

Countries

Austria

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026